Search research articles
Contact Us
Filters
Showing results (361-370 of 501) with videos related to
Page
of 51
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
Jean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
The Lancet. Oncology
|
May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry
Claus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Klinische Padiatrie
|
October 11, 2017
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP)
Sonja Offenmueller, Ulrike Leiter, Benedikt Bernbeck, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions
Thomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
BMC Cancer
|
May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
BMC Cancer
|
April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Translational Medicine
|
April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022
Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Page
of 51
Search research articles
Search
Showing results (361-370 of 501) with videos related to
Sort By:
Page
of 51
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
Jean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
The Lancet. Oncology
|
May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry
Claus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
Klinische Padiatrie
|
October 11, 2017
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP)
Sonja Offenmueller, Ulrike Leiter, Benedikt Bernbeck, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions
Thomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
BMC Cancer
|
May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
BMC Cancer
|
April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Translational Medicine
|
April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022
Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Page
of 51